Maravai LifeSciences (MRVI) vs Perrigo (PRGO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Maravai LifeSciences (MRVI) has outperformed Perrigo (PRGO) over the past year, gaining 124.5% versus a loss of 32.9%. Over five years, PRGO leads with a -67.5% price change compared with -80.0% for MRVI. Maravai LifeSciences is the larger company by market cap ($2.64 billion vs $1.98 billion), about 1.3 times the size.
Perrigo pays a dividend yielding 8.12%, while Maravai LifeSciences does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MRVI | PRGO |
|---|---|---|
| Share price | $7.12 | $14.28 |
| Market cap | $2.64B | $1.98B |
| 1-day change | -4.18% | -1.86% |
| YTD return | +128.62% | +4.53% |
| 1-year return | +124.47% | -32.89% |
| 5-year return | -79.97% | -67.46% |
| Forward P/E | — | 5.95 |
| EPS (TTM) | $-0.53 | $-12.28 |
| Dividend yield | 0.00% | 8.12% |
| Annual dividend | $0.00 | $1.16 |
| Revenue (latest FY) | $185.74M | — |
| Revenue growth (YoY) | -28.34% | — |
| Net income (latest FY) | $-130.77M | — |
| Gross margin | 18.30% | — |
| Operating margin | -115.89% | — |
| Net margin | -70.41% | — |
| 52-week high | $9.42 | $22.02 |
| 52-week low | $2.55 | $9.23 |
| Distance from 52-week high | -24.42% | -35.15% |
| Analyst consensus | buy | none |
| Avg. price target upside | +9.97% | +15.55% |
| Average volume | 3.33M | 2.80M |
| Shares outstanding | 148.99M | 138.37M |
| Employees | 415 | 8,100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MRVI has outperformed PRGO by 157.4 percentage points over the past year.
- Perrigo offers a meaningfully higher dividend yield (8.12% vs 0.00%).
About Maravai LifeSciences
MRVI stock →Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS.
Health Care · Biotechnology: Pharmaceutical Preparations · 415 employees
About Perrigo
PRGO stock →Perrigo Company plc provides over-the-counter health and wellness solutions in the United States, Europe, and internationally. The company operates through Consumer Self-Care Americas and Consumer Self-Care International segments.
Health Care · Biotechnology: Pharmaceutical Preparations · 8,100 employees
MRVI vs PRGO FAQ
Which is bigger, Maravai LifeSciences or Perrigo?
Maravai LifeSciences (MRVI) is larger, with a market capitalization of $2.64B compared with $1.98B for Perrigo (PRGO).
Which stock has performed better over the past year, MRVI or PRGO?
MRVI returned +124.47% over the past 12 months, compared with -32.89% for PRGO (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Maravai LifeSciences or Perrigo?
Perrigo pays a dividend yielding 8.12%, while Maravai LifeSciences does not currently pay a regular dividend.
Are Maravai LifeSciences and Perrigo in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.